Grifols (NASDAQ:GRFS) Shares Gap Up – Should You Buy?

Shares of Grifols, S.A. (NASDAQ:GRFS) gapped up prior to trading on Monday . The stock had previously closed at $7.33, but opened at $7.62. Grifols shares last traded at $7.63, with a volume of 237,353 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Trading Up 5.6 %

The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The firm has a market cap of $5.53 billion, a price-to-earnings ratio of 8.30 and a beta of 0.43. The firm’s fifty day moving average is $8.42 and its 200-day moving average is $8.11.

Institutional Investors Weigh In On Grifols

A number of hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its holdings in shares of Grifols by 49.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after buying an additional 1,135 shares in the last quarter. Signaturefd LLC boosted its stake in Grifols by 66.2% during the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 2,153 shares in the last quarter. HighTower Advisors LLC grew its holdings in Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 1,546 shares during the period. AQR Capital Management LLC acquired a new stake in Grifols in the second quarter worth $89,000. Finally, Chesapeake Capital Corp IL bought a new stake in Grifols in the third quarter valued at $148,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.